Abstract | OBJECTIVE: SUBJECTS AND METHODS: Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months). RESULTS: Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%. Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death. CONCLUSION: These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled.
|
Authors | Fabian Pitoia |
Journal | Arquivos brasileiros de endocrinologia e metabologia
(Arq Bras Endocrinol Metabol)
Vol. 58
Issue 1
Pg. 37-41
(Feb 2014)
ISSN: 1677-9487 [Electronic] Brazil |
PMID | 24728162
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Antineoplastic Agents
- Iodine Radioisotopes
- Phenylurea Compounds
- Niacinamide
- Thyroglobulin
- Sorafenib
|
Topics |
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Bone Neoplasms
(secondary)
- Carcinoma, Papillary
(drug therapy, pathology, radiotherapy, secondary)
- Compassionate Use Trials
- Female
- Follow-Up Studies
- Heart Failure
(chemically induced)
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Lung Neoplasms
(secondary)
- Male
- Middle Aged
- Niacinamide
(adverse effects, analogs & derivatives, therapeutic use)
- Phenylurea Compounds
(adverse effects, therapeutic use)
- Response Evaluation Criteria in Solid Tumors
- Sorafenib
- Thyroglobulin
(blood)
- Thyroid Neoplasms
(drug therapy, pathology, radiotherapy)
- Treatment Outcome
|